Literature DB >> 18566863

EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study.

Gilles Pernod1, José Labarère, Jacqueline Yver, Bernadette Satger, Benoit Allenet, Touffek Berremili, Michèle Fontaine, Guy Franco, Jean Luc Bosson.   

Abstract

BACKGROUND: Long-term oral anticoagulation treatment is associated with potential morbidity. Insufficient patient education is linked to poorly controlled anticoagulation. However the impact of a specific educational program on anticoagulation related morbidity remains unknown.
OBJECTIVE: To evaluate the effect of an oral anticoagulation patient education program in reducing both hemorrhagic and recurrent thrombotic complications. DESIGN/PARTICIPANTS: We conducted a prospective, multicenter open randomized study, comparing an interventional group who received a specific oral anticoagulation treatment educational program with a control group. Eligible patients were older than 18 and diagnosed as having deep vein thrombosis or pulmonary embolism requiring therapy with a vitamin K antagonist for 3 months or more. Our primary outcome was the occurrence of hemorrhagic or thromboembolic events.
RESULTS: During the 3-month follow-up the main outcome criteria were observed 20 times (6.6% of patients), 5 (3.1%) in the experimental and 15 (10.6%) in the control group. Consequently, in multivariate analysis, the cumulative risk reduction in the experimental group was statistically significant (OR 0.25, 95% CI 0.1-0.7, p < 0.01).
CONCLUSIONS: Patient education using an educational program reduced VKA-related adverse event rates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566863      PMCID: PMC2518037          DOI: 10.1007/s11606-008-0690-1

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  25 in total

1.  Testing the equality of two dependent kappa statistics.

Authors:  A Donner; M M Shoukri; N Klar; E Bartfay
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  A "two-step" educational approach for patients taking oral anticoagulants does not improve therapy control.

Authors:  Doris Barcellona; Paolo Contu; Francesco Marongiu
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

3.  Development and validation of an instrument to determine patient knowledge: the oral anticoagulation knowledge test.

Authors:  Mario M Zeolla; Michael R Brodeur; Angela Dominelli; Stuart T Haines; Nicole D Allie
Journal:  Ann Pharmacother       Date:  2006-03-21       Impact factor: 3.154

4.  Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial.

Authors:  Silvy Laporte; Sara Quenet; Andréa Buchmüller-Cordier; Jacqueline Reynaud; Brigitte Tardy-Poncet; Christine Thirion; Hervé Decousus; Patrick Mismetti
Journal:  Thromb Haemost       Date:  2003-03       Impact factor: 5.249

5.  Quality evaluation of the management of oral anticoagulation therapy (OAT): the awareness of treating physicians and the education of patients needs to be improved.

Authors:  Valérie Gras-Champel; Annelise Voyer; Nicolas Guillaume; Céline Lematte; Bertrand Roussel; Charlotte Machu-Prestaux; Michel Andréjak; Jean-Jacques Lefrère
Journal:  Am J Ther       Date:  2006 May-Jun       Impact factor: 2.688

6.  Risks factors for highly unstable response to oral anticoagulation: a case-control study.

Authors:  Gualtiero Palareti; Cristina Legnani; Giuliana Guazzaloca; Valdré Lelia; Benilde Cosmi; Barbara Lunghi; Giovanna Marchetti; Daniela Poli; Vittorio Pengo
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

7.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Authors:  S Schulman; C Kearon
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

8.  A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial.

Authors:  R J Beyth; L Quinn; C S Landefeld
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

9.  Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison.

Authors:  M E Cromheecke; M Levi; L P Colly; B J de Mol; M H Prins; B A Hutten; R Mak; K C Keyzers; H R Büller
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

10.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Authors:  Paul M Ridker; Samuel Z Goldhaber; Ellie Danielson; Yves Rosenberg; Charles S Eby; Steven R Deitcher; Mary Cushman; Stephan Moll; Craig M Kessler; C Gregory Elliott; Rolf Paulson; Turnly Wong; Kenneth A Bauer; Bruce A Schwartz; Joseph P Miletich; Henri Bounameaux; Robert J Glynn
Journal:  N Engl J Med       Date:  2003-02-24       Impact factor: 91.245

View more
  17 in total

1.  A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation.

Authors:  Miney Paquette; Daniel M Witt; Anne Holbrook; Jane Skov; Jack Ansell; Holger J Schünemann; Wojtek Wiercioch; Robby Nieuwlaat
Journal:  Blood Adv       Date:  2019-05-28

Review 2.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  New educational approach for patients on warfarin improves knowledge and therapy control.

Authors:  Alenka Mavri; Nina Ostasevski Fernandez; Anja Kramaric; Katarina Kosmelj
Journal:  Wien Klin Wochenschr       Date:  2015-04-01       Impact factor: 1.704

4.  Impact of information leaflets on behavior of patients with gastroenteritis or tonsillitis: a cluster randomized trial in French primary care.

Authors:  Mélanie Sustersic; Eva Jeannet; Lucile Cozon-Rein; Florence Maréchaux; Céline Genty; Alison Foote; Sandra David-Tchouda; Luc Martinez; Jean-Luc Bosson
Journal:  J Gen Intern Med       Date:  2012-07-25       Impact factor: 5.128

Review 5.  Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.

Authors:  Danielle E Clarkesmith; Helen M Pattison; Phyo H Khaing; Deirdre A Lane
Journal:  Cochrane Database Syst Rev       Date:  2017-04-05

6.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

Review 7.  Impact of target-specific oral anticoagulants on transitions of care and outpatient care models.

Authors:  Ann K Wittkowsky
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

8.  Health Literacy and Atrial Fibrillation: Relevance and Future Directions for Patient-centred Care.

Authors:  Konstantinos N Aronis; Brittany Edgar; Wendy Lin; Maria Auxiliadora Parreiras Martins; Michael K Paasche-Orlow; Jared W Magnani
Journal:  Eur Cardiol       Date:  2017

9.  Evaluation of an interactive program for preventing adverse drug events in primary care: study protocol of the InPAct cluster randomised stepped wedge trial.

Authors:  Maud Keriel-Gascou; Karine Buchet-Poyau; Antoine Duclos; Muriel Rabilloud; Sophie Figon; Jean-Pierre Dubois; Jean Brami; Thierry Vial; Cyrille Colin
Journal:  Implement Sci       Date:  2013-06-19       Impact factor: 7.327

10.  Transitions of care in anticoagulated patients.

Authors:  Franklin Michota
Journal:  J Multidiscip Healthc       Date:  2013-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.